{"entity":{"id":"nct07395063","kind":"trial","name":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","aka":[],"tldr":"A phase 2 trial of camrelizumab in colorectal cancer, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, not yet recruiting.","summary":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. is a phase 2, interventional study registered as NCT07395063 by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, with a registry enrolment figure of 68 participants, started 2026-02-01 and due to reach its primary completion in 2029-02-01. Interventions recorded: Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Progression-free survival (PFS）. Colorectal eligibility wording from the registry: \"* Patients pathologically diagnosed with colorectal cancer;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07395063","url":"https://clinicaltrials.gov/study/NCT07395063"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07395063","phase":"2","setting":"A Single-arm, Open-label Clinical Study of Irinotecan Liposome Combined With Capecitabine, Bevacizumab and Camrelizumab as Second-line or Higher Treatment for Patients With Metastatic Colorectal Cancer","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","enrolled":68,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07395063/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}